
    
      This is a single-center, single-arm, open-label study to evaluate the efficacy and safety of
      topical Radionâ„¢-pdt for treatment of patients with oral verrucous hyperplasia (OVH) or oral
      erythroleukoplakia (OEL).

      Total duration of the study will be up to 40 weeks (from screening throughout study until
      completion) as follows:

        -  Screening (within 2 weeks before dosing)

        -  Treatment period (up to 14 weeks)

        -  Safety follow-up period (within 2 weeks after final treatment)

        -  Follow-up period (final treatment plus 4 weeks, 8 weeks, 16 weeks and 24 weeks
           respectively) All enrolled patients will receive up to 8 treatments (once every two
           weeks) during a maximum of 14-week study treatment period. The treated lesion will be
           clinically evaluated and documented (clinical photograph) at each treatment visit.
    
  